Aldosterone blockade in post-acute myocardial infarction heart failure

Bertram Pitt; Roberto Ferrari; Mihai Gheorghiade; Dirk J. Van Veldhuisen; Henry Krum; John McMurray; Jose Lopez-Sendon

doi:10.1002/clc.4960291004

Aldosterone blockade in post-acute myocardial infarction heart failure

Bertram Pitt^*, Roberto Ferrari, Mihai Gheorghiade, Dirk J. Van Veldhuisen, Henry Krum, John McMurray, Jose Lopez-Sendon

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Development of heart failure (HF) or left ventricular systolic dysfunction (LVSD) significantly increases mortality post acute myocardial infarction (AMI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make clinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HF is presented.

Original language	English (US)
Pages (from-to)	434-438
Number of pages	5
Journal	Clinical Cardiology
Volume	29
Issue number	10
DOIs	https://doi.org/10.1002/clc.4960291004
State	Published - Oct 2006

Keywords

Aldosterone
EPHESUS
Eplerenone
Heart failure
Left ventricular systolic dysfunction
Myocardial infarction

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1002/clc.4960291004

Cite this

@article{5e6f2fef5564402aa7fe35bbc8f0b6c6,

title = "Aldosterone blockade in post-acute myocardial infarction heart failure",

abstract = "Development of heart failure (HF) or left ventricular systolic dysfunction (LVSD) significantly increases mortality post acute myocardial infarction (AMI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make clinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HF is presented.",

keywords = "Aldosterone, EPHESUS, Eplerenone, Heart failure, Left ventricular systolic dysfunction, Myocardial infarction",

author = "Bertram Pitt and Roberto Ferrari and Mihai Gheorghiade and {Van Veldhuisen}, {Dirk J.} and Henry Krum and John McMurray and Jose Lopez-Sendon",

year = "2006",

month = oct,

doi = "10.1002/clc.4960291004",

language = "English (US)",

volume = "29",

pages = "434--438",

journal = "Clinical Cardiology",

issn = "0160-9289",

publisher = "John Wiley and Sons Inc.",

number = "10",

}

TY - JOUR

T1 - Aldosterone blockade in post-acute myocardial infarction heart failure

AU - Pitt, Bertram

AU - Ferrari, Roberto

AU - Gheorghiade, Mihai

AU - Van Veldhuisen, Dirk J.

AU - Krum, Henry

AU - McMurray, John

AU - Lopez-Sendon, Jose

PY - 2006/10

Y1 - 2006/10

N2 - Development of heart failure (HF) or left ventricular systolic dysfunction (LVSD) significantly increases mortality post acute myocardial infarction (AMI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make clinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HF is presented.

AB - Development of heart failure (HF) or left ventricular systolic dysfunction (LVSD) significantly increases mortality post acute myocardial infarction (AMI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make clinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HF is presented.

KW - Aldosterone

KW - EPHESUS

KW - Eplerenone

KW - Heart failure

KW - Left ventricular systolic dysfunction

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=33749613169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749613169&partnerID=8YFLogxK

U2 - 10.1002/clc.4960291004

DO - 10.1002/clc.4960291004

M3 - Review article

C2 - 17063946

AN - SCOPUS:33749613169

SN - 0160-9289

VL - 29

SP - 434

EP - 438

JO - Clinical Cardiology

JF - Clinical Cardiology

IS - 10

ER -

Aldosterone blockade in post-acute myocardial infarction heart failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this